Car T-Cell Therapy
CAR T-cell therapy may be a ‘miracle,’ but it is too soon to say ‘cure’
It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.
Patient with lupus treated with KYV-101 CAR T-cell therapy relapses after 5 months
A patient with lupus nephritis treated with KYV-101, a chimeric antigen receptor T-cell immunotherapy, saw their disease return 5 months after initially showing a response to the treatment, according to the manufacturer.
Benefits of novel CAR T-cell therapy ‘a big deal’ for patients with sarcoma
A novel immunotherapy involving HER2-specific chimeric antigen receptor T cells produced clinically beneficial results for multiple individuals with advanced sarcomas, according to results of a phase 1 trial published in Nature Cancer.
Brain Tumor Awareness Month: Novel treatments exceed expectations, CAR-Ts show promise
May is Brain Tumor Awareness Month.
FDA approves Breyanzi CAR-T for follicular lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.
CAR T-cell therapy remains the 'hottest story' in lupus, autoimmune disease
DESTIN, Fla. — Positive results for chimeric antigen receptor T-cell therapy in systemic sclerosis and myositis have added fuel to the fire of recent landmark data in lupus, said a speaker at the Congress of Clinical Rheumatology East.
‘All-in-one’ CAR-T, stem cell transplantation induces remission in advanced leukemia
A sequential chimeric antigen receptor T-cell therapy and haploidentical hematopoietic stem cell transplantation strategy conferred remissions in certain patients with relapsed or refractory CD7-positive hematologic cancers.
FDA approves earlier use of Carvykti CAR-T for multiple myeloma
The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma.
FDA grants orphan drug designation to CAR T-cell therapy for systemic sclerosis
The FDA has granted orphan drug designation to Cabaletta Bio’s CAR T-cell investigational therapy for the treatment of systemic sclerosis, according to a press release from the manufacturer.
FDA approves Breyanzi CAR-T for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.